PDL BioPharma, Inc. has amended the Royalty Purchase and Sale Agreement with Depomed, Inc. to acquire all of Depomed’s remaining rights to royalties and milestones payable on sales of type 2 diabetes products licensed by Depomed, for as much as $20 million. Under the original agreement PDL would have shared future royalties equally with Depomed after PDL reached $481 million, which PDL expects to occur by October 2020.  PDL has made an initial payment of $10 million to Depomed, and an ...